FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a monoclonal antibody against V-like Ig domain-containing 4 protein (VSIG4) or its antigen-binding fragment, as well as to a composition and an immunoconjugate containing same. Also disclosed is a polynucleotide coding said antibody or its fragment, as well as a cell and a vector containing same. Invention also relates to a method of producing said antibody or fragment thereof, as well as a method for in vitro detection of cancer expressing VSIG4 using said antibody or fragment thereof.
EFFECT: invention is effective for stimulating the immune response in a patient suffering from cancer.
28 cl, 15 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
